Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

0.2235 +0.0097 (+4.54%)

Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 17, 2023

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...

Via Benzinga

Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories ↗

July 17, 2023

Benzinga

Via Benzinga

Why Is Argenx (ARGX) Stock Up 27% Today? ↗

July 17, 2023

Argenx (ARGX) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial of VYVGART Hytrulo.

Via InvestorPlace

Earnings Outlook For Acumen Pharmaceuticals ↗

May 08, 2023

Via Benzinga

US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July ↗

July 17, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket ↗

July 17, 2023

Gainers

Via Benzinga

Acumen Pharma's Stock Doubles In One Session - Here's Why ↗

July 17, 2023

Acumen Pharmaceuticals Inc (NASDAQ: ABOS) presented topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomers (AβO) targeting antibody therapy in...

Via Benzinga

Why Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today? ↗

July 17, 2023

BYND Cannasoft Enterprise (BCAN) stock is dropping on Monday after the company announced an underwritten stock offering.

Via InvestorPlace

Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today? ↗

July 17, 2023

Quoin Pharmaceuticals (QNRX) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change.

Via InvestorPlace

Why Is Acumen Pharmaceuticals (ABOS) Stock Up 46% Today? ↗

July 17, 2023

Acumen Pharmaceuticals (ABOS) stock is on the rise Monday after the company released data from a Phase 1 clinical trial.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 17, 2023

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

Via InvestorPlace

Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 17, 2023

U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease

July 17, 2023

Company to host conference call and webcast for investors and analysts today, July 17, at 8 a.m. ET

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

July 16, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 11, 2023

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 11, 2023

Via Benzinga

Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket ↗

July 11, 2023

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

July 11, 2023

It's time for another breakdown of the biggest pre-market stock movers as we check out all of the shares rising and falling on Tuesday!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 13, 2023

Via Benzinga

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023

June 13, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Market Mixes It Up With A Broad Rally ↗

June 05, 2023

Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive.

Via Talk Markets

A Good Week For The Market But A Pause In The Biotech Rally ↗

May 22, 2023

Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗

May 18, 2023

Via Benzinga

Top 5 Health Care Stocks That May Collapse In Q2 ↗

May 10, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

May 09, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Something Happened In Biotech Last Week ↗

May 08, 2023

Biotech stocks were more constructive last week with some sharp moves up.

Via Talk Markets

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

May 04, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

May 02, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease

March 28, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.